Introduction {#S1}
============

Some hereditary myopathies are known to be variably associated with an unspecific inflammatory response which does not seem to correlate with the extent of myofibre necrosis ([@R01], [@R02]). Eosinophilic myositis is characterized by infiltration of the skeletal muscle tissue (variably an invasion of necrotic muscle fibres) by eosinophils, possibly in association with peripheral blood and/or bone marrow eosinophilia ([@R04]-[@R06]). It is usually attributed to specific causes ([@R03]-[@R05], [@R07]), but if these etiologies are excluded, the diagnosis of idiopathic eosinophilic myositis is made histopathologically. Recently, eosinophilic myositis was suggested to be a pathophysiological component of LGMD2A) ([@R03], [@R07]-[@R10]). Later eosinophilic myositis was reported in LGMD2C, Becker muscular dystrophy, and inflammatory myopathies ([@R11]-[@R13]). This gave rise to the assumption that eosinophil-mediated injury of muscle cells might occur in a wider spectrum of myopathies than previously thought.

In order to get more insight into eosinophilia in skeletal muscle we compared the frequency of eosinophils in patients with five different genetically confirmed myopathies (including LGMD2A), the three idiopathic inflammatory myopathies and amyotrophic lateral sclerosis as a neurogenic disorder.

Patients and methods {#S2}
====================

Patients {#S2a}
--------

Skeletal muscle biopsy samples from the Department of Neurology, Martin-Luther-University Halle- Wittenberg, Germany, were analysed from patients with genetically confirmed myopathies \[LGMD2A (n = 12), LGMD2B (n = 4), LGMD2L (n = 3), facioscapulohumeral muscular dystrophy (FSHD, n = 5), dystrophinopathy (Duchenne (DMD) and Becker (BMD) muscular dystrophy (n = 8)\], histologically confirmed idiopathic inflammatory myopathies (IIM) \[(sporadic inclusion body myositis (sIBM, n = 10) ([@R14]), dermatomyositis (DM, n=11), polymyositis (PM, n = 13) ([@R15])\], amyotrophic lateral sclerosis (ALS, neurogenic control (El Escorial Criteria ([@R16]), n = 11), and normal controls (n = 24, for characterization see legend of [Table I](#T1){ref-type="table"}). Biopsies in IIM cases were performed before any steroid or immunosuppressive treatment was started. All patients and tutors had given their informed consent for the analysis of skeletal muscle biopsy samples.

###### 

Demographic and clinical data of patients. Values are given as median (range). (Normal values: CK women \< 2.41 mmol / L\*s, men \<2.81 mmol / L\*s, eosinophils \<5%.) [^\*^](#T1FN2){ref-type="table-fn"} Kruskal-Wallis One Way Analysis of Variance on Ranks, *post hoc* analysis using Dunn\'s method, n.a. not applicable

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease                                                 Number (n)   Gender (F/M)   Age at biopsy (years)                       Disase duration (years)                     Creatine kinase (μmol/L\*s)               Increased eosinophil count in haemogram (n)
  ------------------------------------------------------- ------------ -------------- ------------------------------------------- ------------------------------------------- ----------------------------------------- ---------------------------------------------
  **Hereditary myopathies**                                                                                                                                                                                             

  LGMD2A                                                  12           4/8            30 (10-72)                                  7\                                          8.3\                                      1/7
                                                                                                                                  (2-49)                                      (2.5-349)                                 

  LGMD2B                                                  4            2/2            43\                                         20\                                         67\                                       0/4
                                                                                      (34-52)                                     (6-22)                                      (38-123)                                  

  LGMD2L                                                  3            1/2            49\                                         6\                                          37\                                       0/3
                                                                                      (29-69)                                     (5-24)                                      (22-74)                                   

  FSHD                                                    5            5/0            39\                                         8(1-19)                                     2.2\                                      1/3
                                                                                      (21-71)                                                                                 (2-12)                                    

  DMD/BMD                                                 8            0/8            11\                                         3(1-13)                                     81\                                       0/3
                                                                                      (3-21)                                                                                  (18-293)                                  

  **Idiopathic inflammatory myopathies**                                                                                                                                                                                

  DM                                                      11           5/6            54\                                         0.5\                                        8.6\                                      1/6
                                                                                      (15-84)                                     (0.1-10)                                    (0.7-227)                                 

  PM                                                      13           7/6            54\                                         1.0\                                        15\                                       0/12
                                                                                      (32-77)                                     (0.3-6)                                     (0.9-112)                                 

  sIBM                                                    10           5/5            70\                                         3\                                          9.4\                                      1/7
                                                                                      (52-77)                                     (1-10)                                      (2-17)                                    

  **Neurogenic control**                                                                                                                                                                                                

  ALS                                                     11           6/5            47\                                         1\                                          8.2\                                      1/7
                                                                                      (35-72)                                     (0.3-4)                                     (2-24)                                    

  **Normal control[^\#^](#T1FN1){ref-type="table-fn"}**   24           13/11          5236\                                       n.a.                                        1.98\                                     0/8
                                                                                      (24-75)                                                                                 (0.6-2.8)                                 

  p[^\*^](#T1FN2){ref-type="table-fn"}                                                \<0.000[^1^](#T1FN3){ref-type="table-fn"}   \<0.000[^2^](#T1FN4){ref-type="table-fn"}   0.002[^3^](#T1FN5){ref-type="table-fn"}   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The normal controls were defined as having myalgia and exertion-induced complaints but no paresis or muscle atrophy, normal creatine kinase levels, normal EMG, and only mild unspecific changes or normal features in muscle biopsy. \* Kruskal-Wallis One Way Analysis of Variance on Ranks, , *post hoc* analysis using Dunn\'s method, n.a. not applicable ALS amyotrophic lateral sclerosis, BMD muscular dystrophy Becker type, DM dermatomyositis, DMD muscular dystrophy Duchenne type, LGMD limb girdle muscular dystrophy, PM polymyositis, sIBM sporadic inclusion body myositis

post hoc analysis:

sIBM, DM, PM vs. DMD/BMD p\<0.05, sIBM vs. LGMD2A, controls;

DM vs. LGMD2A, LGMD2B, LGMD2L,

controls vs. DMD/BMD, LGMD2A, LGMD2B, LGMD2L p\<0.05.

Histochemical and immunohistochemical of skeletal muscle biopsies {#S3}
=================================================================

10-μm serial cryosections from skeletal muscle biopsies were stained with ([@R01]) Giemsa staining ([@R17], [@R18]) and (B) modified hematoxylin and eosin (H&E) ([@R18]) to detect eosinophilic cells ([Fig. 1](#F1){ref-type="fig"}). The modification consisted of a shorter exposure to eosin (modified H&E 3-5s, \"common\" H&E 60s). The number of eosinophils was related to the cross-sectional area and given as eosinophils /mm2. The location of the eosinophils was classified as intravasal, perivascular, endomysial, perifascicular ([Fig. 1](#F1){ref-type="fig"}). Stained sections were visualized using an Axioplan I microscope (Zeiss, Germany), digitized images were acquired for analysis (Axiovision Rel. 4.8.2, Zeiss, Germany). 4-point semi-quantitative histopathological scales were used to score the degree of degeneration, fibrotic changes, and the amount of CD8 (cytotoxic T cells, dilution 1:80, DAKO M7103) and CD68 (macrophages, dilution 1:250, DAKO M0718) positive cells ([@R19]).

###### 

Intravasal (A), perivascular (B), and perifascicular (C) presence of eosinophils in Giemsa staining (20-fold magnification).
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Statistical analysis {#S3a}
--------------------

All data are given as median + 1 SD. All statistical tests were considered to be significant if p \< 0.05. Statistical analyses comprised the Kruskal-Wallis One Way Analysis of Variance on Ranks with Dunn\'s method *posthoc* and the Spearman rank order correlation (Sigma Stat Version 9.0, San Jose, USA).

Results {#S4}
=======

Demographic and clinical data are summarized in [Table 1](#T1){ref-type="table"}. The genetic data of patients with LGMD2A, LGMD2B, LGMD2L, and DMD/BMD are given in supplementary [Table 1](#T1){ref-type="table"}.

The patients with a considerably higher number of eosinophils/mm2 (LGMD2A n = 2, DM n = 2, cut-off: \> 1.0 eosinophils/mm^2^) did not differ in their clinical, genetic or histopathological features compared to other patients with LGMD2A or DM. The number of eosinophils/mm^2^ in LGMD2A and all three IIM (DM, PM, sIBM) was significantly higher than normal controls, but not significantly higher than the other disease groups, using Giemsa staining ([Fig. 2A](#F2){ref-type="fig"}). There was a large overlap in the number of eosinophils/mm2 in LGMD2A, the IIM, and the other myopathies. Eosinophils were detected in 72 cases using Giemsa staining, but in only 31 cases using modified H&E staining ([Fig. 2](#F2){ref-type="fig"}). In controls only one eosinophil was detected in 1 case with both stainings. There was a moderate correlation between the number of eosinophils/mm2 in Giemsa and modified H&E staining (r^2^ 0.58, standard error 0.438, p \< 0.001, power 1.0). Using the cut-off value of 0.3 eosinophils/mm^2^ ([@R20]), 18/100 patients had values \> 0.3 eosinophils/mm^2^ (DM n = 5, PM n = 3, DMD n = 3, LGMD2A n = 3, LGMD2B n = 3, FSHD n = 1).

###### 

Eosinophils/mm^2^ in different myopathies with Giemsa staining (A) and modified H&E staining (B). Data are given as median, 5%, 25%, 75%, 95% CI.

\*Kruskal-Wallis One Way Analysis of Variance on Ranks revealed a statistically significant difference of p \< 0.001 (Giemsa staining) and p = 0.021 (mod. H&E). Pairwise multiple comparison procedures using Dunn\'s method showed a statistically significant difference (p \< 0.05) between LGMD2A, DM, PM, and sIBM with normal controls with Giemsa stain but not with mod. H&E.
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There was no correlation between age at biopsy, duration of the disease or myopathy score with the number of eosinophils/mm^2^ in patients with (i) LGMD2A, (ii) the group of the IIM, or (iii) total group of myopathies together (data not shown). In addition, there was no difference between the extent of myopathic, fibrotic, and inflammatory changes using the semi-quantitative scores between samples with low and high (i.e. mean eosinophils/ mm^2^+1SD) eosinophil count (data not shown).

46% (LGMD2L) to 88% (DM) of all eosinophils were located in the endomysium ([Fig. 3](#F3){ref-type="fig"}). The number of eosinophils located in the vessels, on the passage through the vessel wall and perivascularly ranged from 4% in LGMD2B to 37% in LGMD2L (mostly 15-35%, [Fig. 1](#F1){ref-type="fig"}). Necrotic fibres were not infiltrated by eosinophils.

![Distribution of eosinophils in endomysial (black), intravascular (light grey), perivascular (dark grey), perifascicular (white) locations in the different myopathies and ALS.\
Absolute number of eosinophils: LGMD2A (n = 205), LGMD2B (n = 23), LGMD2L (n = 11), FSHD (n = 13), DMD (n = 45), DM (n = 169), PM (n = 106), sIBM (n = 60), ALS (n = 37), normal controls (n = 1).](1128-2460-32-148-g003){#F3}

Five patients with five different diagnoses had an increased eosinophil count in the haemogram ([Table 1](#T1){ref-type="table"}).

None of these patients had a high number of eosinophils/mm^2^ in the muscle biopsy with Giemsa staining.

Discussion {#S5}
==========

This is the first systematical survey comparing the frequency of eosinophils in a wide variety of inflammatory and hereditary myopathies and ALS. There was a wide range in the number of eosinophils/mm2 in all disorders including ALS. Eosinophilia was neither specific for LGMD2A nor idiopathic inflammatory myopathies. However, we showed that eosinophils are no feature in normal skeletal muscle. The eosinophil density in idiopathic inflammatory myopathies in the present study was similar to the density in a previous study ([@R13]). We found (i) no dominance of eosinophils among the monocytes composing the infiltrates, (ii) no association between high numbers of eosinophils in skeletal muscle and hypereosinophilia in peripheral blood, (iii) no infiltration of necrotic muscle fibres by eosinophils, and (iv) no correlation between the number of eosinophils and the extent of myopathic changes or the duration of the disease. This might be due to the low sample size of these rare disorders and its varying pathological background, but could also reflect the unspecific nature of eosinophils in skeletal muscle.

In the present study, eosinophils were frequently located either within the lumen of the vessel or perivascularly, which might be related to the mechanisms of chemotaxis. It has been suggested that eosinophilic proteins (e.g. eosinophil cation protein) have a specific role in skeletal muscle protein degradation ([@R21], [@R23]) and that eosinophils secrete cytokines, and attract inflammatory cells. In addition, T-lymphocytes, macrophages, monocytes and dendritic cells are able to activate eosinophils ([@R24]).

Eosinophils and fibrosis {#S6}
========================

Eosinophils were frequently seen in the endomysium in the present study, which might be due to mechanisms related to extracellular matrix proteins and their metabolism, finally leading to fibrosis. Eosinophilia in areas of active fibrosis ([@R25]) has been described in a variety of inflammatory diseases ([@R25]-[@R27]). Eosinophils themselves contain granule proteins that might participate in fibrosis ([@R25], [@R28], [@R29]). Fibroblasts are a natural source of the chemokine eotaxin, which is able to attract eosinophils ([@R30]-[@R32]). Fibrosis-related mechanisms might explain why eosinophils were seen in early disease stages in previous reports ([@R03], [@R08]) rather than highly dystrophic muscle in later stages of disease.

Eosinophils in neurogenic disorders {#S7}
===================================

This is the first report to mention eosinophils in skeletal muscle in ALS. Neurotoxic substances generated by eosinophils were suggested to be involved in the development of an axonal neuropathy in Churg-Strauss syndrome ([@R33]). Peripheral nerves have been shown to actively recruit eosinophils via the release of chemotactic factors and expression of adhesion molecules ([@R34], [@R35]). Eosinophil-nerve cell interactions led to generation of neuronal reactive oxygen species and the release of eosinophil proteins ([@R36]). In vivo eosinophils induced neurite retraction and prevented neurite outgrowth during differentiation ([@R37]). Some of these mechanisms might contribute to the axonal damage in motor neurons in motor neuron disease.

In conclusion, the present study suggests that the occurrence of eosinophils in hereditary and idiopathic inflammatory myopathies might not be associated with specific genetic causes (such as mutations in the CAPN3 gene), but rather related to mechanisms related to extracellular matrix proteins and their metabolism, finally leading to fibrosis in skeletal muscle tissue and the degeneration or denervation of skeletal muscle cells.
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###### 

Genetic data of patients with hereditary myopathies. \*In 5 of 8 cases of dystrophinopathy no deletion of the dystrophin gene could be identified, and a point mutation was not investigated so these cases were diagnosed by western blot and immunochemistry for dystrophin. \*\* Heterozygous mutation without detection of another mutation. Cases were diagnosed by western blot.

  ----------------------------------------------------------------------------------------
  Disease / Gene         patient   1^st^ allele                    2^nd^ allele
  ---------------------- --------- ------------------------------- -----------------------
  **LGMD2A /** *CAPN3*   1\        c.200-204delFWSAL\              p.A705H\
                         2\        c.550delA\                      c.550delA\
                         3\        c.550delA\                      n.d.\*\*\
                         4\        c.550delA\                      n.d.\*\*\
                         5\        c.550delA\                      p.V509P\
                         6\        c.550delA\                      n.d.\*\*\
                         7\        c.550delA\                      p.G565Stop\
                         8\        c.550delA\                      p.A355T\
                         9\        c.550delA\                      Intron13 1746-20C\>G\
                         10\       p.Arg490Trp\                    p.Arg489Trp\
                         11\       c.550delA\                      c.550delA\
                         12        p.Gly445Arg                     n.d.\*\*

  **LGMD2B /** *DYSF*    1\        c.2779delG\                     n.d.\*\*\
                         2\        c.763delC\                      c.3059insC\
                         3\        c.1930G\>T in exon 20\          n.d.\*\*\
                         4         c.247dupG                       c.C757T

  **LGMD2L /** *ANO5*    1\        c.191dupA\                      p.R758C\
                         2\        c.191dupA\                      c.191dupA\
                         3         c.191dupA                       c.1898+1G\>A

  **DMD/BMD /** *DMD*    1\        n.d.\*\                         n.\
                         2\        del exons 2-7 (in frame)\       a.\
                         3\        n.d.\*\                         n.a.\
                         4\        n.d.\*\                         n.a.\
                         5\        n.d.\*\                         n.a.\
                         6\        del exons 53-55 (frameshift)\   n.a.\
                         7\        del exons 19-44\                n.a.\
                         8         n.d.\*                          n.a.\
                                                                   n.a.
  ----------------------------------------------------------------------------------------

BMD muscular dystrophy Becker type, DMD muscular dystrophy Duchenne type, LGMD limb girdle muscular dystrophy
